| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Maksim L Maksimov, Andrey A Svistunov, Vadim V Tarasov, Vladimir N Chubarev, Marco Ávila-Rodriguez, George E Barreto, Olga V Dralova, Gjumrakch Alie. Approaches for the Development of Drugs for Treatment of Obesity and Metabolic Syndrome. Current pharmaceutical design. vol 22. issue 7. 2016-10-31. PMID:26648466. |
in this context, drugs affecting the central and peripheral mediator systems such as cannabinoid receptor antagonists (rimonabant), neuronal reuptake inhibitor of ne and 5 ht (sibutramine), neuronal reuptake inhibitor of ne 5-ht da (tesofensine), agonist of 5 ht 2c receptors (lorcaserin) have a high risk of side effects on the central nervous and cardiovascular systems when used for a long period. |
2016-10-31 |
2023-08-13 |
Not clear |
| Scott A Briggs, Brandon J Hall, Corinne Wells, Susan Slade, Paul Jaskowski, Margaret Morrison, Amir H Rezvani, Jed E Rose, Edward D Levi. Dextromethorphan interactions with histaminergic and serotonergic treatments to reduce nicotine self-administration in rats. Pharmacology, biochemistry, and behavior. vol 142. 2016-10-31. PMID:26704812. |
we have found in the rat model that the h1 histamine antagonist pyrilamine and the serotonin 5ht2c agonist lorcaserin also significantly reduce nicotine self-administration. |
2016-10-31 |
2023-08-13 |
rat |
| Colin Harvey-Lewis, Zhaoxia Li, Guy A Higgins, Paul J Fletche. The 5-HT(2C) receptor agonist lorcaserin reduces cocaine self-administration, reinstatement of cocaine-seeking and cocaine induced locomotor activity. Neuropharmacology. vol 101. 2016-10-05. PMID:26427596. |
the 5-ht(2c) receptor agonist lorcaserin reduces cocaine self-administration, reinstatement of cocaine-seeking and cocaine induced locomotor activity. |
2016-10-05 |
2023-08-13 |
rat |
| Colin Harvey-Lewis, Zhaoxia Li, Guy A Higgins, Paul J Fletche. The 5-HT(2C) receptor agonist lorcaserin reduces cocaine self-administration, reinstatement of cocaine-seeking and cocaine induced locomotor activity. Neuropharmacology. vol 101. 2016-10-05. PMID:26427596. |
lorcaserin (lorqess, belviq(®)) is a selective 5-ht(2c) receptor agonist that has received fda approval for the treatment of obesity. |
2016-10-05 |
2023-08-13 |
rat |
| Gongliang Zhang, Xian Wu, Yong-Mei Zhang, Huan Liu, Qin Jiang, Gang Pang, Xinrong Tao, Liuyi Dong, Robert W Stackma. Activation of serotonin 5-HT(2C) receptor suppresses behavioral sensitization and naloxone-precipitated withdrawal symptoms in morphine-dependent mice. Neuropharmacology. vol 101. 2016-10-05. PMID:26432939. |
lorcaserin, a 5-ht(2c)r agonist, prevented the induction and expression, but not the development, of morphine-induced behavioral sensitization. |
2016-10-05 |
2023-08-13 |
mouse |
| Suzanne Higgs, Alison J Cooper, Nicholas M Barne. The 5-HT₂C receptor agonist, lorcaserin, and the 5-HT₆ receptor antagonist, SB-742457, promote satiety; a microstructural analysis of feeding behaviour. Psychopharmacology. vol 233. issue 3. 2016-08-29. PMID:26507195. |
whilst the fda-approved anorectic, lorcaserin and various 5-hydroxytryptamine (5-ht)6 receptor antagonists reduce feeding, a direct assessment of their impact upon feeding behaviour is less clear. |
2016-08-29 |
2023-08-13 |
Not clear |
| Fiona D Zeeb, Guy A Higgins, Paul J Fletche. The Serotonin 2C Receptor Agonist Lorcaserin Attenuates Intracranial Self-Stimulation and Blocks the Reward-Enhancing Effects of Nicotine. ACS chemical neuroscience. vol 6. issue 7. 2016-04-19. PMID:25781911. |
the serotonin 2c receptor agonist lorcaserin attenuates intracranial self-stimulation and blocks the reward-enhancing effects of nicotine. |
2016-04-19 |
2023-08-13 |
rat |
| Fiona D Zeeb, Guy A Higgins, Paul J Fletche. The Serotonin 2C Receptor Agonist Lorcaserin Attenuates Intracranial Self-Stimulation and Blocks the Reward-Enhancing Effects of Nicotine. ACS chemical neuroscience. vol 6. issue 7. 2016-04-19. PMID:25781911. |
lorcaserin, a serotonin (5-hydroxytryptamine, 5-ht) 2c receptor agonist, was recently approved for the treatment of obesity. |
2016-04-19 |
2023-08-13 |
rat |
| Gregory T Collins, Lisa R Gerak, Martin A Javors, Charles P Franc. Lorcaserin Reduces the Discriminative Stimulus and Reinforcing Effects of Cocaine in Rhesus Monkeys. The Journal of pharmacology and experimental therapeutics. vol 356. issue 1. 2016-03-15. PMID:26534942. |
lorcaserin has serotonin (5-ht)2c receptor agonist actions, is approved by the u.s. food and drug administration for treating obesity, and might be effective for treating cocaine abuse. |
2016-03-15 |
2023-08-13 |
monkey |
| Katherine M Serafine, Kenner C Rice, Charles P Franc. Directly Observable Behavioral Effects of Lorcaserin in Rats. The Journal of pharmacology and experimental therapeutics. vol 355. issue 3. 2016-02-09. PMID:26384326. |
(1r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine (lorcaserin) is approved by the united states food and drug administration for treating obesity, and its therapeutic effects are thought to result from agonist activity at serotonin (5-ht)2c receptors. |
2016-02-09 |
2023-08-13 |
rat |
| Amir H Rezvani, Marty C Cauley, Edward D Levi. Lorcaserin, a selective 5-HT(2C) receptor agonist, decreases alcohol intake in female alcohol preferring rats. Pharmacology, biochemistry, and behavior. vol 125. 2015-07-28. PMID:25109272. |
lorcaserin, a selective 5-ht(2c) receptor agonist, decreases alcohol intake in female alcohol preferring rats. |
2015-07-28 |
2023-08-13 |
rat |
| Sheldon H Preskor. CNS drug development: lessons from the development of ondansetron, aprepitant, ramelteon, varenicline, lorcaserin, and suvorexant. Part I. Journal of psychiatric practice. vol 20. issue 6. 2015-07-17. PMID:25406050. |
the neurotransmitter systems on which the development of these agents were based included serotonin for ondansetron and lorcaserin, dopamine for varenicline, substance p (or neurokinin) for aprepitant, melatonin for ramelteon, and orexin for suvorexant. |
2015-07-17 |
2023-08-13 |
Not clear |
| Vanessa Cousins, Jed E Rose, Edward D Levi. IV nicotine self-administration in rats using a consummatory operant licking response: sensitivity to serotonergic, glutaminergic and histaminergic drugs. Progress in neuro-psychopharmacology & biological psychiatry. vol 54. 2015-05-12. PMID:24953434. |
in the current study, using the operant licking nicotine self-administration model with young adult sprague-dawley rats (0.03mg/kg/infusion of nicotine), we tested the effect of antagonists of h1 histamine receptors pyrilamine, serotonin (5ht) type 2 receptors ketanserin and n-methyl-d-aspartate (nmda) glutamate receptors with d-cycloserine as well as an agonist of 5ht2c receptors lorcaserin, in dose ranges that we have found in previous studies to significantly reduce iv nicotine self-administration with the operant lever press operand. |
2015-05-12 |
2023-08-13 |
rat |
| Jong Kil Joo, Kyu Sup Le. Pharmacotherapy for obesity. Journal of menopausal medicine. vol 20. issue 3. 2015-01-12. PMID:25580419. |
lorcaserin is a serotonin 2c receptor agonist. |
2015-01-12 |
2023-08-13 |
Not clear |
| Luke K Burke, Barbora Doslikova, Giuseppe D'Agostino, Alastair S Garfield, Gala Farooq, Denis Burdakov, Malcolm J Low, Marcelo Rubinstein, Mark L Evans, Brian Billups, Lora K Heisle. 5-HT obesity medication efficacy via POMC activation is maintained during aging. Endocrinology. vol 155. issue 10. 2015-01-05. PMID:25051442. |
we next investigated whether age-related diminished arc pomc activity therefore impacts the potency of 5-ht obesity pharmacotherapies, lorcaserin, d-fenfluramine, and sibutramine and report that all compounds reduced food intake to a comparable extent in both chow-fed young lean (3-5 months old) and middle-aged obese (12-14 months old) male and female mice. |
2015-01-05 |
2023-08-13 |
mouse |
| Ryan T Hurt, Jithinraj Edakkanambeth Varayil, Jon O Ebber. New pharmacological treatments for the management of obesity. Current gastroenterology reports. vol 16. issue 6. 2014-12-29. PMID:24828101. |
lorcaserin is a novel serotonin 5-ht2c selective agonist which has been shown in three phase iii studies to significantly reduce weight and cardiovascular risk factors such as diabetes. |
2014-12-29 |
2023-08-13 |
human |
| Grace Shyh, Angela Cheng-La. New antiobesity agents: lorcaserin (Belviq) and phentermine/topiramate ER (Qsymia). Cardiology in review. vol 22. issue 1. 2014-09-30. PMID:24304809. |
lorcaserin is a serotonin agonist, whereas phentermine/topiramate is a combination of a sympathomimetic agent and an antiepileptic drug; both these agents have been shown to reduce weight significantly and improve cardiovascular and metabolic parameters, such as blood pressure, lipids, and hba1c. |
2014-09-30 |
2023-08-12 |
Not clear |
| Chuan Chen, Michael G Ma, Cody L Fullenwider, Weichao G Chen, Abu J M Sadequ. Biopharmaceutics permeability classification of lorcaserin, a selective 5-hydroxytryptamine 2C agonist: method suitability and permeability class membership. Molecular pharmaceutics. vol 10. issue 12. 2014-07-21. PMID:24102111. |
biopharmaceutics permeability classification of lorcaserin, a selective 5-hydroxytryptamine 2c agonist: method suitability and permeability class membership. |
2014-07-21 |
2023-08-12 |
human |
| Chuan Chen, Michael G Ma, Cody L Fullenwider, Weichao G Chen, Abu J M Sadequ. Biopharmaceutics permeability classification of lorcaserin, a selective 5-hydroxytryptamine 2C agonist: method suitability and permeability class membership. Molecular pharmaceutics. vol 10. issue 12. 2014-07-21. PMID:24102111. |
lorcaserin, marketed in united states as belviq, is a selective human 5-hydroxytryptamine 2c agonist used for weight management. |
2014-07-21 |
2023-08-12 |
human |
| Sean Manning, Andrea Pucci, Nicholas Fine. Pharmacotherapy for obesity: novel agents and paradigms. Therapeutic advances in chronic disease. vol 5. issue 3. 2014-06-24. PMID:24790728. |
the development of these drugs as antiobesity agents has followed varying paths, ranging from lorcaserin, a selective serotonin agent, exploiting the beneficial central actions of fenfluramine but without the associated systemic side effects, to liraglutide, a gut hormone already used as a glucose-lowering drug but with appetite-suppressant properties, or the novel drug combination of phentermine/topiramate, two 'old' drugs used in lower doses than with previous therapeutic uses, resulting in an additive effect on weight loss and fewer side effects. |
2014-06-24 |
2023-08-13 |
Not clear |